摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-溴-1-萘甲酸乙酯 | 33500-78-6

中文名称
8-溴-1-萘甲酸乙酯
中文别名
——
英文名称
ethyl 8-bromonaphthalene-1-carboxylate
英文别名
Ethyl 8-bromo-1-naphthoate
8-溴-1-萘甲酸乙酯化学式
CAS
33500-78-6
化学式
C13H11BrO2
mdl
——
分子量
279.133
InChiKey
OVVPVFKLUFMBJB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    52 °C
  • 沸点:
    369.3±15.0 °C(Predicted)
  • 密度:
    1.437±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    8-溴-1-萘甲酸乙酯四(三苯基膦)钯potassium carbonate 、 sodium hydroxide 作用下, 以 1,4-二氧六环乙醇 为溶剂, 反应 22.0h, 生成 8-甲基萘-1-羧酸
    参考文献:
    名称:
    [EN] 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN
    [FR] SAXITOXINES 11,13-MODIFIÉES DESTINÉES AU TRAITEMENT DE LA DOULEUR
    摘要:
    本文提供了化合物、包含这些化合物的药物组合物、制备这些化合物的方法,以及在治疗与电压门控钠通道功能相关的疾病中使用这些化合物和组合物的方法。这些化合物是根据式(I)中的11,13-改性沙雌毒素,其中R1、X1和X2如本文所述。
    公开号:
    WO2018183782A1
  • 作为产物:
    描述:
    1-萘甲酸乙酯 在 sodium persulfate 、 N-溴代丁二酰亚胺(NBS)三氟甲磺酸 、 palladium diacetate 作用下, 以 1,2-二氯乙烷 为溶剂, 反应 1.0h, 以80%的产率得到8-溴-1-萘甲酸乙酯
    参考文献:
    名称:
    区域和化学选择性C ?弱配位的H氯化/缺电子芳烃的溴化和相对方向基团能力的研究
    摘要:
    都是相对的:已经开发了一种实用而有效的Pd II催化的区域和化学选择性氯化/溴化反应,可轻松合成各种芳族氯化物。该反应显示出优异的反应活性,良好的官能团耐受性和高收率。进行了一项初步研究,以评估各种功能的相对指导能力。
    DOI:
    10.1002/anie.201300176
点击查看最新优质反应信息

文献信息

  • [EN] 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN<br/>[FR] SAXITOXINES MODIFIÉES 11,13 POUR LE TRAITEMENT DE LA DOULEUR
    申请人:SITEONE THERAPEUTICS INC
    公开号:WO2020072835A1
    公开(公告)日:2020-04-09
    Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): (Formula (I)); where R1, and R2 are as described herein.
    本文提供了化合物、包含该化合物的药物组合物、制备该化合物的方法,以及在治疗与电压门控通道功能相关的疾病中使用该化合物和组合物的方法,其中该化合物是根据式(I)的11,13-修饰沙雌毒素:(式(I));其中R1和R2如本文所述。
  • Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
    申请人:Galley Guido
    公开号:US20070197621A1
    公开(公告)日:2007-08-23
    The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.
    本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法,包括向个体施用化合物I的治疗有效量,其中R、R1、R2、A和n如规范中所定义,以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。
  • Peri Interaction in Naphthalene Ketones
    作者:Masao Kubo、Takeo Sato
    DOI:10.1246/bcsj.52.3314
    日期:1979.11
    Peri interaction in several naphthalene ketones was investigated using the carbon-13 NMR, IR, and UV spectra. The carbonyl carbon resonances for 7H, 14H-cycloocta[1,2,3-de:5,6,7-d′e′]dinaphthalene-7,14-dione and its 7-oxa analog were found to be shifted upfield by 27 and 24 ppm respectively compared with those of model compounds. The anomalous shift for the former was attributed to π-orbital compression
    使用碳 13 NMR、IR 和 UV 光谱研究了几种酮中的 Peri 相互作用。发现 7H, 14H-cycloocta[1,2,3-de:5,6,7-d'e']dinaphthalene-7,14-dione 及其 7-oxa 类似物的羰基碳共振通过与模型化合物相比,分别为 27 和 24 ppm。前者的异常位移归因于 π 轨道压缩,由于强制平行几何结构抑制了羰基的极化,而后者归因于场效应。该结论得到了紫外和红外数据的支持。
  • 4-IMIDAZOLINES
    申请人:Galley Guido
    公开号:US20090012138A1
    公开(公告)日:2009-01-08
    The present invention relates to compounds of formula wherein R 1 , R 2 , X, Y and Ar are as defined herein and to their pharmaceutically active salts, with the exclusion of the racemic compound 4-benzyl-4,5-dihydro-1H-imidazole or its tautomer (CAS 131548-83-9). Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    本发明涉及式I的化合物,其中R1,R2,X,Y和Ar如此定义,并且它们的药物活性盐,但排除外消旋化合物4-苄基-4,5-二氢-1H-咪唑或其互变异构体(CAS 131548-83-9)。式I的化合物具有良好的迹胺相关受体(TAARs)亲和力,尤其是对TAAR1,可用于治疗抑郁症,焦虑症,双相情感障碍,注意力缺陷多动障碍(ADHD),与压力相关的障碍,精神障碍,如精神分裂症,神经疾病,如帕森病,神经退行性疾病,如阿尔茨海默病,癫痫,偏头痛,高血压,物质滥用和代谢性疾病,如进食障碍,糖尿病,糖尿病并发症,肥胖症,脂质代谢异常,能量消耗和吸收障碍,体温稳态障碍和功能障碍,睡眠和昼夜节律障碍,以及心血管疾病。
  • ORGANIC METAL COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND
    申请人:LG DISPLAY CO., LTD.
    公开号:US20220127288A1
    公开(公告)日:2022-04-28
    The present disclosure relates to an organic metal compound having the following structure of Formula 1, an organic light emitting diode (OLED) and an organic light emitting device that includes the organic metal compound. The OLED and the organic light emitting device including the organic metal compound can improve their luminous efficiency, luminous color purity and lifespan.
    本公开涉及具有以下结构的Formula 1有机属化合物,有机发光二极管(OLED)和包括该有机属化合物的有机发光装置。包括该有机属化合物的OLED和有机发光装置可以提高其发光效率、发光颜色纯度和寿命。
查看更多